Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384909 | 0.89 | TAAR1 (0.55) | TAAR1ADRA1ACYP1A2KDM4EATM | |
| Hydrochloric Acid SCHEMBL1437384 | 0.87 | TAAR1 (0.53) | TAAR1ADRA1ACYP1A2KDM4EATM | |
| SCHEMBL34463016 | 0.85 | TAAR1 (0.52) | TAAR1ADRA1ACYP1A2AOC3HTR2A | |
| SCHEMBL1253168 | 0.85 | AOC3 (0.64) | TAAR1ADRA1ACYP1A2AOC3HTR2A | |
| Hydrochloric Acid SCHEMBL7084948 | 0.83 | AOC3 (0.45) | CYP1A2AOC3KDM4E | |
| Hydrochloric Acid SCHEMBL7366474 | 0.83 | AOC3 (0.62) | TAAR1ADRA1ACYP1A2AOC3HTR2A | |
| SCHEMBL7725428 | 0.80 | TAAR1 (0.41) | TAAR1ADRA1ACYP1A2HTR2A | |
| SCHEMBL12071515 | 0.80 | TAAR1 (0.46) | TAAR1ADRA1ACYP1A2HTR2AHTR2C | |
| SCHEMBL5712533 | 0.80 | TAAR1 (0.50) | TAAR1ADRA1ACYP1A2AOC3HTR2A | |
| SCHEMBL1159639 | 0.80 | TAAR1 (0.50) | TAAR1ADRA1ACYP1A2AOC3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183349-A1 | BIISOQUINOLINE COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-0455006-B1 | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles | AMERICAN CYANAMID CO (US) | 1999-07-07 | — | — | EP | disclosed |
| US-5373020-A | Antidiabetic, antiobesity, hyperglycemic agents | AMERICAN CYANAMID COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| US-5245053-A | Resolution of diastereoisomers, reaction with Mosher's acid hypoglycemic agent, diabetes | AMERICAN CYANAMID COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| US-5151439-A | Antidiabetic agents or antihyperglycemic agents | AMERICAN CYANAMID COMPANY (US) | 1992-09-29 | — | — | US | disclosed |
| US-5106867-A | Administering substituted 1,3-benzodioxole antilipogenic agent | AMERICAN CYANAMID COMPANY (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0455006-A2 | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles | AMERICAN CYANAMID COMPANY (US) | 1991-11-06 | — | — | EP | disclosed |
| US-5061727-A | ANTIOBESITY, ANTIDIABETIC, HYPOGLYCEMIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1991-10-29 | — | — | US | disclosed |
| EP-0022330-B1 | SYNERGISTIC ANTIHYPERTENSIVE COMPOSITIONS | SMITHKLINE BECKMAN CORPORATION (US) | 1983-12-21 | — | — | EP | disclosed |
| EP-0002327-B1 | PHARMACOLOGICALLY ACTIVE 6-LOWER ALKYL-7,8-DIHYDROXY-1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, METHOD OF PREPARING THEM AND INTERMEDIATES | SMITHKLINE BECKMAN CORPORATION (US) | 1982-08-04 | — | — | EP | disclosed |
| US-4342686-A | Intermediates for preparing 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines | SMITHKLINE CORPORATION (US) | 1982-08-03 | — | — | US | disclosed |
| US-4265889-A | DOPAMINERGIC, HYPOTENSIVE | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0022330-A2 | Synergistic antihypertensive compositions | SMITHKLINE BECKMAN CORPORATION (US) | 1981-01-14 | — | — | EP | disclosed |
| US-4206210-A | PARKINSON'S DISEASE | SMITHKLINE CORPORATION (US) | 1980-06-03 | — | — | US | disclosed |
| EP-0002327-A1 | Pharmacologically active 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, method of preparing them and intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-13 | — | — | EP | disclosed |
| US-4031079-A | Intermediates for 2-aminobenzodiazepine-5-ones | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-06-21 | — | — | US | disclosed |
| US-4022767-A | 2-Aminobenzodiazepine-5-ones | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-05-10 | — | — | US | disclosed |
| US-4020055-A | Intermediates for 2-aminobenzodiazepine-5-ones | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-04-26 | — | — | US | disclosed |
| US-4002610-A | 2-Aminobenzodiazepine-5-ones | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183349-A1 | BIISOQUINOLINE COMPOUNDS AND METHODS OF TREATMENT | MKI67, MCL1, MYC | TAAR1 4002/4885ADRA1A 2563/4885CYP1A2 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.